Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
Sponsored by Ono Pharmaceutical Co. Ltd
About this trial
Last updated 8 months ago
Study ID
ONO-7475-03
Status
Active, not recruiting
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
20+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 4 years ago
What is this trial about?
This study is to evaluate the tolerability and safety of ONO-7475 in combination with
osimertinib in the first-line treatment of patients with EGFR-mutated, stage IIIB/IIIC/IV
or recurrent non-small cell lung cancer (NSCLC), which is unsuitable for radical
irradiation.
What are the participation requirements?
Inclusion Criteria
1. Patients with stage IIIB/IIIC/IV or recurrent NSCLC, which is unsuitable for radical irradiation
2. Patients with confirmed EGFR gene exon 19 deletion or EGFR gene exon 21 mutation(L858R)and who are scheduled to receive osimertinib
3. Patient has an ECOG performance status of 0-1
Exclusion Criteria
1. Patients with severe complication
2. Patients with multiple primary cancers